OPTIMISING MOLECULAR DIAGNOSIS AND PRECISION THERAPY IN PATIENTS WITH ADVANCED NSCLC HARBOURING RARE ONCOGENIC TRANSLOCATIONS

Chair
Zofia Piotrowska, Boston, MA, USA
Co-Chair
Antonio Calles, Madrid, Spain

WEDNESDAY, 20 MARCH 2024
18:15 - 19:45 CET, FORUM HALL

18:15 Welcome and introduction
Zofia Piotrowska
Boston, MA, USA

18:25 Tissue and liquid-based next-generation sequencing diagnostics for patients with advanced NSCLC: Platforms, timings and issues with tissues
Antonio Calles
Madrid, Spain

18:45 Molecular Reports in advanced NSCLC: How to optimise report structure, molecular tumour board input and actionability
Ales Ryska
Hradec Králové, Czech Republic

19:05 Optimal therapeutic regimens for advanced NSCLC patients with rare oncogenic translocations (beyond ALK) and insights on resistance upon retesting
Zofia Piotrowska
Boston, MA, USA

19:25 Q&A and discussion
All speakers

19:40 Concluding remarks
Antonio Calles
Madrid, Spain

This educational activity is provided by ESMO and supported by Eli Lilly and Company.